Cognition Therapeutics

CGTX49

Penny Stock

$0.42arrow_drop_down1.40%-$0.00

Penny Stock

CGTX49

$0.42

arrow_drop_down1.40%-$0.00

Penny Stock

Performance History

Key Stats
Open	$0.42
Prev. Close	$0.42
EPS	-0.96
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$17.77M
PE Ratio	-

	LOW	HIGH
Day Range	0.41	0.68
52 Week Range	0.39	2.95

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.96

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Cognition Therapeutics (CGTX)

Cognition Therapeutics, Inc. (CGTX) is a biopharmaceutical company focused on the development of innovative therapeutics for the treatment of neurodegenerative disorders. The company's primary focus is on developing small molecule drugs that can target the underlying causes of Alzheimer's disease. CGTX is dedicated to addressing the significant unmet medical needs of patients suffering from cognitive impairment and neurodegeneration.

The company's lead candidate, CT1812, is a first-in-class small molecule drug that has shown promise in preclinical studies. CT1812 is designed to selectively inhibit the toxic oligomer formation of the protein beta amyloid, which is known to play a critical role in the development and progression of Alzheimer's disease. By targeting beta amyloid oligomers, CGTX aims to prevent the synaptic damage and cognitive decline associated with the disease.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Ms. Lisa Ricciardi
Headquarters: Purchase
Employees: 22
Exchange: NASDAQ

Keep an eye on Cognition Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Cognition Therapeutics's (CGTX) price per share?

The current price per share for Cognition Therapeutics (CGTX) is $0.42. The stock has seen a price change of -$0.01 recently, indicating a -1.4% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Cognition Therapeutics (CGTX)?

For Cognition Therapeutics (CGTX), the 52-week high is $2.95, which is 599.05% from the current price. The 52-week low is $0.4, the current price is 6.3% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Cognition Therapeutics (CGTX) a growth stock?

Cognition Therapeutics (CGTX) has shown an average price growth of -3.36% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cognition Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Cognition Therapeutics (CGTX) stock price performance year to date (YTD)?

As of the latest data, Cognition Therapeutics (CGTX) has a year-to-date price change of -78.25%. Over the past month, the stock has experienced a price change of -28.46%. Over the last three months, the change has been -39.97%. Over the past six months, the figure is -83.45%.

help

Is Cognition Therapeutics (CGTX) a profitable company?

Cognition Therapeutics (CGTX) has a net income of -$25.79M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$50.72M. Furthermore, the EBITDA is -$58.61M.

help

What is the market capitalization of Cognition Therapeutics (CGTX)?

Cognition Therapeutics (CGTX) has a market capitalization of $17.77M. The average daily trading volume is 0.57, indicating the stock's liquidity and investor engagement.

News

COGNITION THERAPEUTICS

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

CATALYST ACCELERATOR OGDEN

DEPARTMENT OF THE AIR FORCE DIGITAL TRANSFORMATION OFFICE

DIGITAL MODERNIZATION

Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office

CALENDAR OF EVENTS

Jul 2, 2024

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

PRODUCT / SERVICES ANNOUNCEMENT

May 21, 2024

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

EARNINGS RELEASES AND OPERATING RESULTS

May 7, 2024

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

CLINICAL STUDY

Apr 29, 2024

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About Cognition Therapeutics (CGTX)

Keep an eye on Cognition Therapeutics

Frequently Asked Questions

What is Cognition Therapeutics's (CGTX) price per share?

What is the 52-week high and low for Cognition Therapeutics (CGTX)?

Is Cognition Therapeutics (CGTX) a growth stock?

What is Cognition Therapeutics (CGTX) stock price performance year to date (YTD)?

Is Cognition Therapeutics (CGTX) a profitable company?

What is the market capitalization of Cognition Therapeutics (CGTX)?

News

Take Your Investments to a Whole New Level